Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 489

1.

The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.

Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, Desai M, Miller M, Hall SD.

Clin Pharmacol Ther. 2004 Jan;75(1):89-100.

PMID:
14749695
2.

The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.

Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD.

Clin Pharmacol Ther. 2001 Oct;70(4):317-26.

PMID:
11673747
3.

The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.

Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, Hall SD.

Clin Pharmacol Ther. 2003 Sep;74(3):275-87. Erratum in: Clin Pharmacol Ther. 2004 Mar;75(3):249.

PMID:
12966371
4.

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.

Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, Hall SD.

Clin Pharmacol Ther. 1998 Aug;64(2):133-43.

PMID:
9728893
5.

In vivo effects of interleukin-10 on human cytochrome P450 activity.

Gorski JC, Hall SD, Becker P, Affrime MB, Cutler DL, Haehner-Daniels B.

Clin Pharmacol Ther. 2000 Jan;67(1):32-43.

PMID:
10668851
6.

In vivo effect of clarithromycin on multiple cytochrome P450s.

Bruce MA, Hall SD, Haehner-Daniels BD, Gorski JC.

Drug Metab Dispos. 2001 Jul;29(7):1023-8.

7.
8.

Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.

Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ.

Clin Pharmacol Ther. 1999 Nov;66(5):461-71.

PMID:
10579473
9.

Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.

Lee JI, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW, Frye RF.

Clin Pharmacol Ther. 2002 Dec;72(6):718-28.

PMID:
12496753
10.

Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping.

Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML Jr, Kulawy RW, Beck DJ, Bertino JS Jr.

Clin Pharmacol Ther. 1998 Sep;64(3):257-68.

PMID:
9757149
11.

Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.

Mouly SJ, Matheny C, Paine MF, Smith G, Lamba J, Lamba V, Pusek SN, Schuetz EG, Stewart PW, Watkins PB.

Clin Pharmacol Ther. 2005 Dec;78(6):605-18.

PMID:
16338276
12.

Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.

Walzer M, Bekersky I, Blum RA, Tolbert D.

Pharmacotherapy. 2012 Apr;32(4):340-53. doi: 10.1002/j.1875-9114.2012.01028.x. Epub 2012 Mar 15.

PMID:
22422635
13.

Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.

Turpault S, Brian W, Van Horn R, Santoni A, Poitiers F, Donazzolo Y, Boulenc X.

Br J Clin Pharmacol. 2009 Dec;68(6):928-35. doi: 10.1111/j.1365-2125.2009.03548.x.

14.

The interaction between St John's wort and an oral contraceptive.

Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC.

Clin Pharmacol Ther. 2003 Dec;74(6):525-35.

PMID:
14663455
15.

CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism.

Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR.

Clin Pharmacol Ther. 2000 Jul;68(1):82-91.

PMID:
10945319
16.

Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo.

Lowry JA, Kearns GL, Abdel-Rahman SM, Nafziger AN, Khan IS, Kashuba AD, Schuetz EG, Bertino JS Jr, van den Anker JN, Leeder JS.

Clin Pharmacol Ther. 2003 Mar;73(3):209-22.

PMID:
12621386
17.
18.

Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists.

Martínez C, Albet C, Agúndez JA, Herrero E, Carrillo JA, Márquez M, Benítez J, Ortiz JA.

Clin Pharmacol Ther. 1999 Apr;65(4):369-76.

PMID:
10223772
19.

An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A).

Palmer JL, Scott RJ, Gibson A, Dickins M, Pleasance S.

Br J Clin Pharmacol. 2001 Nov;52(5):555-61.

20.

Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity.

Shadle CR, Lee Y, Majumdar AK, Petty KJ, Gargano C, Bradstreet TE, Evans JK, Blum RA.

J Clin Pharmacol. 2004 Mar;44(3):215-23.

PMID:
14973304

Supplemental Content

Support Center